Maruti Suzuki's Q2FY24 Financial Performance Review

In this financial performance review, we delve into the results of Maruti Suzuki for the second quarter of fiscal year 2024 and analyze key metrics, including revenue, expenses, net profit, and margin.


ParticularsQ2FY23(Y-o-Y) % changeQ1FY24(Q-o-Q) % changeQ2FY24
Total Income (₹crs.)30,54124.133,31613.7737,902
Expenses (₹crs.)27,92518.5730,1479.8433,112
Net Profit (₹crs.)2,11278.222,52549.073,764
Margin (%)6.923.027.582.359.93


Maruti Suzuki reported a total income of ₹37,902 crores for Q2FY24, indicating a strong 13.77% increase sequentially. Furthermore, the company achieved substantial year-on-year revenue growth, with an impressive 24.1% rise compared to the same quarter in the previous fiscal year.


Expenses for Maruti Suzuki in Q2FY24 amounted to ₹33,112 crores, representing a notable 9.84% increase compared to the preceding quarter. On a year-on-year basis, the company's expenses grew by 18.57%, reflecting the possible impact of inflation and other cost factors.


The net profit of Maruti Suzuki for Q2FY24 was ₹3,764 crores, demonstrating robust growth and a significant 49.07% increase compared to the preceding quarter. On a year-on-year basis, the company's net profit exhibited a remarkable 78.22% growth, indicating efficient cost management and strong sales performance.


Maruti Suzuki's margin in Q2FY24 was 9.93%, showcasing steady improvement with a 2.35% increase sequentially. Year-on-year, the company's margin exhibited a notable 3.02% growth, highlighting the success of their strategies and operations.


In conclusion, Maruti Suzuki's financial performance in Q2FY24 reflects a strong and efficient operation, delivering impressive revenue growth and improved margins. Their ability to manage costs and capitalize on market opportunities has contributed to robust profits. 


Stay tuned for more detailed updates on Maruti Suzuki's financial performance in the coming quarters.

Top stories

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM


Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM


RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs

Share Market


12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read

Share Market


15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions